PROGENICS PHARMACEUTICALS IN's ticker is PGNX and the CUSIP is 743187106. A total of 100 filers reported holding PROGENICS PHARMACEUTICALS IN in Q4 2014. The put-call ratio across all filers is 0.25 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2020 | $500,000 | -32.3% | 131,590 | -9.4% | 0.00% | -100.0% |
| Q4 2019 | $739,000 | -15.1% | 145,230 | -15.6% | 0.00% | 0.0% |
| Q3 2019 | $870,000 | -50.0% | 172,128 | -38.9% | 0.00% | 0.0% |
| Q2 2019 | $1,739,000 | +85.2% | 281,847 | +39.2% | 0.00% | 0.0% |
| Q1 2019 | $939,000 | -14.3% | 202,455 | -22.4% | 0.00% | 0.0% |
| Q4 2018 | $1,096,000 | +26.3% | 260,838 | +88.3% | 0.00% | 0.0% |
| Q3 2018 | $868,000 | -56.3% | 138,495 | -44.0% | 0.00% | -50.0% |
| Q2 2018 | $1,987,000 | +49.5% | 247,099 | +38.7% | 0.00% | +100.0% |
| Q1 2018 | $1,329,000 | +15.2% | 178,206 | -8.2% | 0.00% | 0.0% |
| Q4 2017 | $1,154,000 | +31.1% | 194,031 | +62.3% | 0.00% | 0.0% |
| Q3 2017 | $880,000 | +14.6% | 119,566 | +5.8% | 0.00% | 0.0% |
| Q2 2017 | $768,000 | -19.7% | 113,053 | +11.7% | 0.00% | 0.0% |
| Q1 2017 | $956,000 | +46.0% | 101,249 | +33.5% | 0.00% | 0.0% |
| Q4 2016 | $655,000 | +403.8% | 75,836 | +233.4% | 0.00% | – |
| Q3 2015 | $130,000 | -71.1% | 22,745 | -62.3% | 0.00% | -100.0% |
| Q2 2015 | $450,000 | +77.9% | 60,275 | +42.6% | 0.00% | 0.0% |
| Q1 2015 | $253,000 | -63.9% | 42,266 | -54.4% | 0.00% | 0.0% |
| Q4 2014 | $701,000 | -5.5% | 92,729 | -35.1% | 0.00% | -50.0% |
| Q3 2014 | $742,000 | +58.2% | 142,881 | +31.2% | 0.00% | +100.0% |
| Q2 2014 | $469,000 | +6.3% | 108,877 | +0.9% | 0.00% | 0.0% |
| Q1 2014 | $441,000 | +44.6% | 107,928 | +88.6% | 0.00% | 0.0% |
| Q4 2013 | $305,000 | – | 57,219 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|